BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 7954465)

  • 1. Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model.
    Gottstein C; Schön G; Tawadros S; Kube D; Wargalla-Plate UC; Hansmann ML; Wacker HH; Berthold F; Diehl V; Engert A
    Cancer Res; 1994 Dec; 54(23):6186-93. PubMed ID: 7954465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
    Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
    Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
    Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
    Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
    Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
    Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay.
    Yoshida M; Rybak RJ; Choi Y; Greenberg SJ; Barcos M; Kawata A; Matsuno F; Tsai H; Seon BK
    Cancer Res; 1997 Feb; 57(4):678-85. PubMed ID: 9044845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
    Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
    Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA
    Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
    Griffin T; Raso V
    Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma.
    Griffin TW; Richardson C; Houston LL; LePage D; Bogden A; Raso V
    Cancer Res; 1987 Aug; 47(16):4266-70. PubMed ID: 3496960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
    Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
    Hara H; Luo Y; Haruta Y; Seon BK
    Cancer Res; 1988 Aug; 48(16):4673-80. PubMed ID: 2969282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice.
    Schnell R; Katouzi AA; Linnartz C; Schoen G; Drillich S; Hansmann ML; Schiefer D; Barth S; Zangemeister-Wittke U; Stahel RA; Diehl V; Engert A
    Int J Cancer; 1996 May; 66(4):526-31. PubMed ID: 8635869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer.
    Calvete JA; Newell DR; Wright AF; Rose MS
    Cancer Res; 1994 Sep; 54(17):4684-90. PubMed ID: 8062265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
    Ettenson D; Sheldon K; Marks A; Houston LL; Baumal R
    Anticancer Res; 1988; 8(4):833-8. PubMed ID: 3263079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
    Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
    Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ; Uhr JW; Vitetta ES
    Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved pharmacokinetics and tumor localization of immunotoxins constructed with the Mr 30,000 form of ricin A chain.
    Trown PW; Reardan DT; Carroll SF; Stoudemire JB; Kawahata RT
    Cancer Res; 1991 Aug; 51(16):4219-25. PubMed ID: 1868442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.
    Wawrzynczak EJ; Cumber AJ; Henry RV; May J; Newell DR; Parnell GD; Worrell NR; Forrester JA
    Cancer Res; 1990 Dec; 50(23):7519-26. PubMed ID: 2253201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.